IE833010L - Dihydropyridines - Google Patents
DihydropyridinesInfo
- Publication number
- IE833010L IE833010L IE833010A IE301083A IE833010L IE 833010 L IE833010 L IE 833010L IE 833010 A IE833010 A IE 833010A IE 301083 A IE301083 A IE 301083A IE 833010 L IE833010 L IE 833010L
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- product
- hours
- alkyl
- exaaple
- Prior art date
Links
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 99
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- -1 trlfluoromethyl Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000000047 product Substances 0.000 description 106
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 238000004458 analytical method Methods 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 50
- 239000012458 free base Substances 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 21
- 239000002585 base Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000007810 chemical reaction solvent Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
- JAYUDPKFDQGKFQ-UHFFFAOYSA-N n,n-diethylethanamine;ethanol Chemical compound CCO.CCN(CC)CC JAYUDPKFDQGKFQ-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- UCTNTYHJFWMUBD-UHFFFAOYSA-N 4-chloro-3-oxobutanoic acid Chemical compound OC(=O)CC(=O)CCl UCTNTYHJFWMUBD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- KTVPZBURNBMJNW-UHFFFAOYSA-N ethyl 4-(2-azidoethoxy)-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)COCCN=[N+]=[N-] KTVPZBURNBMJNW-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- BAQKJENAVQLANS-UHFFFAOYSA-N fenbutrazate Chemical compound C=1C=CC=CC=1C(CC)C(=O)OCCN(C1C)CCOC1C1=CC=CC=C1 BAQKJENAVQLANS-UHFFFAOYSA-N 0.000 description 1
- 229960002533 fenbutrazate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- CZRWOPRGDPUSDE-UHFFFAOYSA-N methyl 4-bromo-3-oxobutanoate Chemical compound COC(=O)CC(=O)CBr CZRWOPRGDPUSDE-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
This Invention relates to certain dihydropyrldines, specifically to certain 1,4-dlhydropyridinea having a heterocyclic group In a side chain attached to the 2-position, which have utility as antl-lschaaulc and antihypertensive agents.
The compounds of the Invention reduce the ftsNsnt of calcium into the cell and they are thus able to delay or prevent the cardiac contracture which is believed to be caused by an accumulation of intracellular calcium under ischaemlc conditions. Excessive calcium Influx during lschaemla can have a number of additional adverse effects which would further compromise the ischaemlc myocardium. These include less efficient use of oxygen for ATP productioni activation of mitochondrial fatty acid oxidation and possibly, promotion of cell necrosis. Thus the compounds are useful in the treatment or prevention of a variety of cardiac conditions, such as angina pectoris, cardiac arrythmias, heart attacks and cardiac hypertrophy. The compounds also have vasodilator activity since they can inhibit calcium influx in cells of vascular tissue and they are thus also useful as antihypertensive agents and for the treatment of coronary vasospasm. .
Patent Specification No. describes certain dihydrcFyr-
idine calciun antagonists having a secondary or tertiary amino group at the end of a side chain attached to the 2-positlon.
According to the present invention there are provided dihydropyrldlnes of the formula:-
H ooc
— (I)
ai3 N CH.-O-Y-NHR3
II *
and their pharmaceutically acceptable acid addition salts;
wherein R is a phenyl group optionally substituted by one or two substituents each independently selected from nitro, halo, Cj-C^
alkyl, C^-C^ alkoxy, hydroxy, trifluoronetliyl, and cyano;
1 2
R and R arc each independently C^-C^ alkyl or 2-methoxyetliy];
Y is -(CH2)2-;
R3 is attached to the adjacent nitrogen atom by a carbon atom 15 and is either (a) a monocyclic 5- or 6-membered hciterocycle containing at least one N atom and optionally one or two.further heteroatoms or groups each independently selected from 0 0
O, S, S, N and N, and is optionally substituted by Cj-C^ alkyl, Cj-C^ alkoxy, halo, hydroxy, oxo, cyano, 3-(Cj-C^ alkyl)ureldo.
A 5
phenyl, phenoxy, pyridyl, nrccyl* (Cj-C^ n1koxy)cArbonyJ, -MR R ,
-S(>2NRAR5 or -CONR-*R5 when- either R* and R5 arc each
4 5
independently II or .-tlkyJ or R and R together with the nitrogen atom tn which they are attached represent a saturated 5-or 6-membered heterocyclic group optionally containing a further heteroatom or group selected from 0, S, NH, N(Cj-C^ alkyl) and NCHO; or (b) a blcycllc group which is an optionally substituted 5- or 6-membered heterocycle as defined in (a) fused to an imidazole or benzene ring, said benzene ring being optionally substituted by Cj-C^ alkyl, Cj—C/( alkoxy or halo.
The pli.irnincciitir.illy acceptable acid addition salts of the compounds of the formula (1) are those formed from acids which form non-toxic acid addition salts, for example the hydrochloride, hydrobromidc, sulphate or bisulphate, phosphate or acid phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate and tartrate salts.
"Halo" meanR F, CI, Br or I.
Alkyl and alkoxy groups having 3 or more carbon atoms can be straight or branched chpin.
R is preferably a phenyl group substituted by 1 or 2 substltuents selected from halo and CF^. R Is more preferably 2-chlorophenyl, 2,3-dichlorophenyl or 2-chloro-3-trifluoromcthyphenyl. R Is most preferably 2,3-dlchlorophenyl.
Preferably clthor R* Is CIl^ and R^ is C^Hj or R* is C^Hj and R^ is CH.j. Most preferably, R^ is CH^ and R^ Is C^Rj.
3
R Is preferably « heterocyclic group selected from triuzolyl, oxadinziilyl., pyrlmldlnyl or ;i partially saturated derivative thereof, puflnyl, qulnazolinyl, lmldazolyl, imldazollnyl, trlazinyl, pyridyl, thlazolyl, tliiazoXlnyl,
benzthinzolyl, thladiazolyl, pyrazlnyl, quinoxalinyl and
3
pyrrolinyl, and their N- .-iud S-oxides, R being optionally substituted by C^-C^ alkyl, C^-C^ alkoxy, halo, hydroxy, oxo, cyano, 3-methylureldo, phenyl, phenoxy, pyridyl, acetyl,
4 S
carbamoyl, N-methylcarbamoyl, (Cj-C^ alkoxy)cnrbonyl, -NR R; , or
4 5 4 5
-SOjNR R , where cither R and R are each independently H or
■ 4 5
Cj-C^ alkyl or R and K together with the nitrogen atom to which they are attached form a ptperldino, morphollno, 4-methylpiperazin-l-yl or 4-formylpiperazin-l-yl group.
1,2,4-Triazol-3-yl, 1,2,4-oxadiaiol-3-y1, 1,2,5-thladlarol-3-yl, pyrimldin-2-yl, pyrimldin-4-y1, lmidazol-2-yl, 1,3,5-trlasin-2-yl, pyrld-2-yl, thlazol-2-yl, pyraiin-2-yl and pyrrolln-2-yl, optionally substituted as above, represent typical
3
Instances of R .
The most preferred l&divldual heterocyclic groups represented
3
by K are as follows:-
N—N N— o m—s H
-4. JL. -^\ -f
■4
o
-Q- ■ -rt,. _n
CHj O
H.
v
-Q • <0 J?
MOT,' " m7 ' N_^ , N—k
H 2 H O H O '
NH
IF -* « _/ 2 o
J-f _y""<
mr # v
»-< • -L> • . -O
»h2
-K. "'X' O O" X3 • -6 . >>
H-CHO \ /
<5
if\*3 A
^ W
Km/
B.
OH
<y
N — N B
■ -OL
- COCH,
O-Ph and I |)
J JsAiPr ■
In mm of these groups tautomerisa may occur, e.g.
-Q - "Q
H O OH
In such cases both taatomera are within the scope of this invention.
In the preferred individual compound, K is
12 3
2,3-dichloroph«rnyl • R Is CH^> R is CgHy T is R
NH
H 2
The compounds of the formula (I) containing one or sore asymmetric centres will exist as one or more pairs of enantiomers, and such pairs or individual 1Sonera nay be separable by physical methods, e.g. by fractional crystallisation of the free bases or suitable salts or chromatography of the free bases. The Invention Includes the separated pairs as well as mixtures thereof, as racealc mixtures or as separated optically-active isonerlc forma.
The compounds of the invention can be prepared by a number of routes, including the followlng:-
(1) The compounds of the formula (I) can be prepared via che following route
.2 , H ^ . R
1 H __2 . , H . ^ H
CH, ' CB.OKMH, _ ^
COOR2
"3 £ *-2" 2 CH3 N ' CHjOTNH.R3
CBjOKMHJ
(ID <«
Q la i facile leaving group, such aa -HH.NO^, C^-C^
alkylthio, Cj-C^ alkoxy, cl, Br or I. Q la preferably methylthlo, nethoxy, ethoxy, chloro or nlcroawlno.
The reaction la typically carried out by heating the reactanta at 50-130'C, e.g. under reflox, In a suitable organic aolvent until the reaction la substantially complete. Typical organic aolventa Include methanol, ethanol, n-butanol,
acetonltrlle, dlmethylformamld* (OMF), methylene chloride, etc. -When Q la C^-C^ alkylthlo, Cl, Br or I, the presence of a base such as trlethylaaln*, sodium carbonate or 4-dlmetfcylamlnopyridlna la preferred. The product (I) can than be Isolated and purified conventionally.
The starting materials of the formula (II) are the subject matter of our Patent Specification No. v . . . Some typical methods for their preparation are however deacrlbed in the Preparations hereinafter.
Aa disclosed in. the said Patent Specification, a typical route to the Intermediates (II) la as followss-
h3<-y-och2coch2coor'
,2
COCR
.2
H
/
C'
+ R. CHO +
0
CHjOVNj
(II)
An alternative route to the internedlatas (u) is as followa:-
(«)
^ COOR2
X *
) CH-C1
COOR' o
HO-Y-N
v
<b)
r ooc . h
CH.
^00011
IJ + R.CHO + j 0
"v OT2O™^J^|
ROOC
CH
COOR
(c)
ROOC
.COOR"
R H R H
, 9 hydrazinahydrate/ethanol, . , / .
■■^ • COOR —: -*■ ROOC ^
or aqueous mstbylaaine
CH
CH, N CH.OYH
' H 2
3 jj ""20YNH2
(II)
Preparations 16 and 17 describe particularly useful routes to 2,3-dlchlorobcnzaldehyde and 2-chloro-3-trifluoromethylbenz-aldetayde. 2KMoro-3-tKifluoronethylbenzald^Tyde is the street of BP-A-0 145 334.
.3 —
(2) Compounds In which R Is N |
~^N HH,
H— O
4. A
V—CH.OYN H
N.CN
N
CH-O-Y-N-C-X H
can be prepared as follovs:-
— (Ill)
NBjOH/CajOH
MBjOB.BCl/Et
-~-ch2O-Y m
-^nAH,
X Is -SCHj, -OCH^ or -0.Phenyl.
These reactions are typically carried out in a suitable organic solvent Such as methanol, ethanol, acetonltrlle or tetrahydrofuran, with heating If necessary at up to 130*C and preferably under reflux. Heating Is preferred when ethanol Is used as the solvent. The reaction Is generally conplete In about 4 hours. The desired product can then be Isolated and purified conventionally.
The starting Materials of the foranla (III) can be prepared from compounds of the formula (II) .[see route (1) above] as follows i.CN H.CN
II
'WCH20YKH2 X-C-X, .IWCH.O-Y-K-C-X
Isopropanol or methanol, root* (II) temperature, ft hours.
(3) Compounds In which R la
-f
S-^
can be ptepared from the compounds of the foranla (II) as follows nJXr-CHjOTNHj Cl. CH-CH^MCS ^ rw CHj-O-Y-N-^
(XI)
The reaction la typically carried out by stirring the reactants together is a suitable organic solvent, e.g. methylene 10 chloride, for a few hours, and again the product can then be
Isolated and purified conventionally. The presence of base la the reaction mixture, e.g. trlethylsalne. Is preferred.
(4) Compounds In which R is
(C1-C4 alkyl)
<i
COOtC^-C^ alkyl)
or
-<
-n <i can be prepared as follows:-
"it coca
CHj N CHjOYN-C-NHJ
B B
(IV)
C1.CH2CH0
or Sr.ca2flto
,^-CH.OYH
<3
(XV) Bgta2COCOO.(C1-C4 alkyl)
or CICHjCOCOO.(Cx-C4 alkyl)
(XV) Clta2CO(Cl-C4 alkyl)
or BrCH2CO(C^-C^ alkyl)
CHjOYN
-wnj- CH201M'
rfl
COO(C1-C4 alkyl)
(Cx-C4 alkyl)
(1T) BrCHjCOOEt or
CICHjCOOEt
~rw- CHjOTO-^
S—
The reaction Is typically carried oat by stirring the reactancs together ac room temperature In a sulcable solvent, e.g. CHCl^/CH^OH, until the reaction is substantially complete. If 10 necessary, the reaction mixture can be heated to accelerate the reaction. The product can be Isolated conventionally.
The. starting materials of the formula (IV) can be prepared from the compounds of the formula (II) as follows:-
S
I
«W-CH2<J*KH2 Cl-C-Cl ^~-CH-.OYN-OS
CaCOj| CH^Cl^/H^O|
(II) room temperature
NH3/EtOB.
heat. 2>5 hours t s ^ I
CHjOYBCSHJ
^ NH
(IV)
(5) Compounds in Which R3 Is | can be prepared follows:-
wCH2<mm-l!-»Hco2c2H5 i) CH3I ^CH2OYHH-^ :a*a!j^0H ^
11) hydrazine 8 H
hydrate
The starting ethoxycarbonylthioureldo derivatives can be prepared as follows
S II
rMv-C^OTHHj S-C"N-CO.Et^ njw CH^OTNH-C-NHCO^C^Hj.
3
(6) Compounds in vhich R Is
-a " "O""
H 3 CH3
can ba prapared by the reaction of the correapondlng talao
3
compound (R - H) with 5-acetyl-2-amlno-oxasole In aqueoua ■ethanol. typically by heating for 24 houra or so. The reaction
3
S producea a mixture of two products having R aa above. These can be separated by conventional chromatographic procedures.
(7) Soma of the conpounda of the formula (I) can' be prepared from
3
other conpounda of the formula (I), e.g., those where R la a heterocyclic group subatltuted by an [C^-C^ alley 1] carbamoyl group
can be prepared by the reaction of the correapondlng conpounda In which the heterocyclic group la subatltuted by (Cj-C^
alkoxy)carbonyl with a C^-C4 alkylamina. Similarly, conpounda in which R3 la substituted by -IHj can be prepared by reacting the correapondlng methoxy-substltuted derivatives with ammonia,
IS generally in ethanol, and conpounda in which R3 Is substituted by
-NHCONM(Cx-C4 alkyl) by reaction of tha corresponding amlno-aubatltuted compound with a C^-C4 alkyllaocyanate.
3
Compounds in which R Is a heterocyclic group subatltuted by an amino or aubatltuted amino group, or a cyclic amino group, e.g. 20 morphollno, plperldlno or N-methyl plperazlno, can be prepared by heating the correapondlng chloro-aubstltutad compound with the appropriate amine.
3
Compounds in which R is pyrazlnyl can be prepared by the
3
reduction of the correapondlng compound In which R is a 25 pyrazlne-N-oxlde with aodlum dlthionlte, e.g. by heating In aqueous ethanol.
and (8) Acid addition salts can be prepared conventionally, e.g. by reacting a solution of the free base In a suitable organic solvent with a solution of the desired acid la a suitable solvent, and either recovering the salt by filtration when It precipitates from solution, or by evaporation of the solution to dryness.
The ability of the compounds to inhibit the movement of calcium Into the cell is shown by their effectiveness in reducing the response of Isolated heart tissue to an Increase la calcium ion concentration In vitro. The test is performed by mounting spirally cut strips of rat aorta with one end fixed and the other attached to a force transducer, the tissue is lamersed In a bath of physiological saline solution containing potassium ions at a concentration of 45 allllmolar and no calcium. Calcium chloride Is added to the bath with a pipette to give a final calcium ion concentration of 2 millimolar. The change In tension caused by the resulting contraction of the tissue is noted. The bath is drained and replaced with fresh saline solution and, after 45 minutes, the test Is repeated with the particular compound under test.present in the saline solution. The concentration of compound required to reduce the response by 50Z (ICjq) Is recorded.
The antihypertensive activity of the conpounda la also evaluated after oral administration by measuring the fall In blood pressure in spontaneously hypertensive rats or renally hypertensive dogs.
For administration to nan In the curative or prophylactic treatment of cardiac conditions and hypertension, oral dosages of the compounds will be in the range of from 5-100 mg dally for an average adult patient (70 kg), typically 10-60 mg dally. Thus for a typical adult patient, individual tablets or capsules will generally contain from S, 10 or 20 mg of active compound, in a suitable pharaaceutlcally acceptable vehicle or carrier. Dosages for Intravenous administration will typically be within the range 1 to 10 mg per single dose as required. In practice the physician will determine the actual dosage which Will be most suitable for an Individual patient and It will vary with the age, weight and response of the particular patient. The above dosages ate exemplary of the average case but there can, of course, be individual Instances where higher or lower dosages ranges are merited, and such are within the scope of this invention.
For human use, the conpounda of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the Intended route of administration and standard pharmaceutical practice. For example, they may be administered orally In the form of tablets containing such exclplents as starch or lactose, or in capsules or ovules either alone or in admixture with exclplents, or In the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example. Intravenously, Intramuscularly or subcutaneously. For parenteral administration, they are best used
In the forn of a sterile aqueous solution which nay contain othet substances, for example, enough salts or glucose to make the .. solution Isotonic.
Thus In a further aspect the Invention provides a 5 pharmaceutical composition comprising a compound of the formulA
(I), or a pharmaceutical^ acceptable acid addition salt thereof, together with a pharmaceutical^ acceptable diluent or carrier.
The invention also includes a compound of the formula (I), or a pharmaceutical^ acceptable acid addition salt thereof, for use 10 in medicine, In particular in the treatment of iachaemic heart disease, angina, or hypertension in a human being.
The following Examples Illustrate the Invention. All temperatures are In °C:-
EXAMPLE 1
A. H- ^2-[ (4-1^2-Chlorophenyl^ -3-ethoXYcarbonvl-S-ttethoxv-carbonyl-6-methyl-l.4-dlhydropyrid-2-vl)aethoxy]ethylj^ -H'-cyano-S-methyl-laothlourea
Cu-=i~
xc
MaOOC «nr» MeOOC
2-(2-Amlnoethojty«!«thyll-3-ethorycarbonyl-4-(2-chloro-phenyl)-5-BethoxycArbonyl-6-nethyl-l,4-dihydropyridine (4.3 g) and 10 dimethyl N-cyanolmldodithlocarbonate (2 g) In isopropanol (IS ml) were allowed to stand at room temperature for 4 hours. Ether (30 ml) was than added and the mixture was stood at room temperature . overnight. The crystalline precipitate was filtered, washed with ether and dried, yield of the title compound 5.0 g, m.p. 177-179*.
IS
Analysis Z:-
Found: C,54.35; H.5.4; H.11.2
Calculated for C^HjjCIN^S: C.54.5; H.5.4; H,11.05.
B. 2 - f 2- (3-Aalno-1.2.4--trlarol-5"ylamlno) eth0xvm3thyl] -4-12-chlorophenyl)-3-ethoxTcarbonyl-5-«iethoxycarbonyl-6~aathyl-1.4-dlhydropyrldlne
M—X. X
: ^
H- ^2-[ (4-^ 2-Chlorcrpheayl^ -3-ethoxycarbony 1-5-oetboxy-
carbonyl-6-methyl-l,4-dlhydropyrld-2-yl)methoxy]ethyl^ -a'-cyano-S-sethyl-lsothlourea (0.4 g) and hydrazine hydrate (0.15 al) were dissolved in ethanol (20 al) and heated under reflux for 3 hoars. The solvent was then evaporated and toluene (10 al) was added to 10 the residue, and again the solution was evaporated to dryness. The residue was chroaacographed on Merck "Klaselgel 60H" (Tirade Mark), eluting with 22 aethanol in aethylene chloride, to give a beige solid. The solid was reerystalllaed froa ethyl acetate plus a trace of ether to give the title coapouikd, yield 0.1 g, m.p. 15 137-138*.
Analysis'
Found: C.53.45; H.5.5; H.17.2
Calculated for C^H^ClNgOji C.53.8; H.5.55; H.17.1.
Part (A) was repeated using (MeO^ON.CN In place of (MeS)2OH.CN and using the same reaction conditions. The resulting intermediate had -OMe in place of -SMe, and this Intermediate was converted by the method of part (B), i.e. using hydrazine hydrate, to the title compound of part (B).
EXAMPLE 2
2-[ 2-(3-Amlno-].2.4-tojazol-5-jylan)lno)ethbxvmethvll -4- (2-chlono -3 - trifluoroaethylphei»yl)-3-ethoxycarboayl-5-iiethoXycarbonyl-6-m-ethy1-1.4-dlhydropyridine
2-(2-Aminoethoxymethyl)-4-(2-chloro-3-trlfluoroi»ethyl-pheryl)->3-etto^carixD^l-S-inethcoycarixMyl-e^-inethyl-l ,4-dlliydK^iyridlne (0.5 g) and dimethyl N-cyanolnldodlthiocarbonate (0.16 g) in lsopropanol (5 ml) were stirred together at room temperature for 4 hours. Ether (10 ml) was then added and the mixture was stirred for a further 2 hours. The precipitated lsothiourea was filtered, washed with dry ether, dried and used directly without further
purification. The solid was dissolved in ethanol (10 ml) and heated to reflux while hydrazine hydrate (0.2 ml) was added in three portions. After 3 hours at reflux, the solution was evaporated to dryness and the residue was crystallised from ethyl acetate to give the title.compound, m.p. 144-145*.
Anal2sls_Z.:-
Found: C.,49.4; H.4.7; N.15.0
Calculated for CjjHjgClFjNgOj: C.49.6; H.4.7; N.15.0.
A. The following compound, a.p. 215-217*, was prepared similarly to Example 1A, but starting from the corresponding 4-(2,3-dichlorophenyl)-1,4-dlhydropyrldyl derivative:
EXAMPLE 3
Cl
CHjCOC
ca.
'3
Analysis Z;-
Found: C.50.7; H.5.05; N.10.1
Calculated for C^HjgCl^OjSsC,51.02; H.4.85; H.10.35.
>. This compound was then reacted with hydrazine hydrate according to the procedure of Exaaple IB to produce the following product, m.p. 195-6*:-
N —N
■ AA
. 1/4 ethyl acetate
Analysis Z:-Found:
C.50.2; H.5.35; H.15.6
Calculated for C22H26Cl2M605.l/4 C^gOji C.50.45; H,5.15i N.15.35.
EXAMPLE 4
The following compound, n.p. 110-111*, was prepared similarly to Example IB, but using methyl hydrazine
AnalyslB Z:-
Found: C.54.1; H.5.8; N.16.3
Calculated for C^H^ClHgOj.JiHjO: C.53.7; H.5.9; 16.35.
EXAMPLE 5
Tha following compound m.p. 118-120.5" was prepared similarly Co Example 3B, but using methyl hydrazine
, Me
M — N.'
.>>b2o
Analysis t:-
Found: C.50.6; H.5.3; N.IS.O
Calculated for c23H28C12N6°5-llH20: c»50'4> H>5-3! H.15.3.
EXAMPLE 6
2-[ 2-(5-Aalno-l, 2.4-oxadla«ol-3-ylamlno)ethoxyethyl1-4-{2-chloro-phenyl)-3-etKoxycarbonyl-5-aethoxycarbonyl-6-eiethyl-1.4-dlhydro-pyrldlne
N— O
:A.A,
nh.
The S'-cyano-S-raethyl-isothiourea froa Example 1A (0.4 g) and hydroxylaaiae (0.2 g) In methanol (20 ml) were heated under reflux for 3 hours. The solvent was then evaporated, and the residue was chromatographed on "Kleselgel 60H" (Trade Mark), elutlng with chloroform to give a solid which was recrystalllsed from 1:1 toluene/ether to give the title compound, yield 0.29 g, m.p. 135*.
Analysis.X:-
Found: C.53.8; H,5.4; 8,14.25
Calculated for C^fl^ClHjOg: C.53.7; H.5.3; N.14.25.
The following compound, m.p. 114*, was prepared similarly to
2-chloro-3-trlfluoromethyl isothlourea intermediate as prepared in Example 2:-
' examfle7
the procedure of Example 6 but using the corresponding chjooc ch,
3
Analysis I:-Found:
Calculated for jCIFjNjOj:
C.49.6; H.4.7; N.12.4 C.49.3; H.4.5; M.12.5.
28 -
EXAMPLE 8
4-i2-Chlorophenyl)-3-ethoxycarbopyl-5-«cthoxyc>rbonyl-6-eethyl-2-I2-(3.A-dlhydro-4-oio-pyrlmldln-2-ylanlno)ethoxyacthyll-1,4-dl-hydropyrldlne
2-[2-Aminoethoxyi»atliyl]-3-«thoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-»ethyl-l,4-dihydTopyridlne (0.7S g) and 2-isethylthi0-3H-pyriald-4-0Q« (0.5 g) were dissolved in ethanol (5 ml) and heated under reflux for 20 hours. The solvent was 10 evaporated and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with 2H hydrochloric acid to remove any unreacted amine, and then with dilute sodium hydroxide solution. It was then washed with water, dried, filtered and evaporated to give a yellow gum. 15 Chromatography on silica "Kleselgel 60H" (Trade Mark) eluting with ethyl acetate gave the title compound, which was recrystalllsed from ethyl acetate, yield 171 mg, m.p, 148-150".
Analysis X:-
Fouttd: C,57.3; H.5.55; H.11.6
Calculated for C^^CWjO^. C.57.3; H,5.4; H,11.15.
H O
- 29 -EXAMPLES 9-36
The following compounds were prepared similarly co the previous exaaple. I.e., by Che following reaction
and ware characterised la Che form indicated:-
Example Mo.
R3
Q
Reaction Solvent
Base
Reaction Time
Form Isolated m.p. (•c)
Analysis % (Theoretical in brackets) c h n
9
n _
n -1^ b 0
MeS-
EtOH
Et3N
4 hrs.
Free base
155-157
55.8 5.55 11.3 (56.25 5.55 11.4)
n
-O
C1
chjch
Na2C03
6 hrs.
Free base
137
59.05 5.7 11.3 (59.2 5.6 11.5)
11
n=knh2
Cl
MeOH
EtjH
12 hrs.
Free base .
186-189
53.25 5.5 18.6 (53.3 5.45 18.9)
V-
1
Exanple Mo.
R3
Q
Reaction Solvent
Base
Reaction Tine
Form Isolated
■.p.
CC)
Analysis X (Theoretical in brackets) C R.N
12
-O"
Cl n-BuOH
EtjH
60 hrs.
Free base
225
56.5 5.4 11.05 (57.35 5.4 11.15)
• 13
Cl n-BuOH
Kt3H
60 hrs.
Free base
172-174
57.2 5.8 13.8 (57.4 5.6 13.95)
_/N=\
—4 NH o
Cl n-BuOH
EtjM
18 hrs.
Free base
120-122
56.9 5.3 10.9 (57.35 5.4 11.15)
_/~c »
■ o Me
Cl n-BuOH
EtjN
18 hrs.
Free base, H2O
122
55.2 5.85 9.8 (55.25 5.9 9.9)
Example No.
R3
Q
Reaction Solvent
Base
Reaction Tine
Torn Isolated m.p.
CC)
Analysis X (Theoretical in brackets) C H H
16
N"^
:vr
N^NH
Cl
CH3CN
H.2C°3
hrs.
Free base
153-155
56.9 5.15 15.9 (57.0 5.2 15.95)
17
OMe
Cl n-BuOH
EtjM
hrs.
Free base
205-207
57.35 5.3 8.9 (58.8 5.4 9.15)
18
Cl
Cl
MeOH
EtjM
2 hrs.
Free base
160
55.35 5.2 10.9 (55.3 5.0 10.75)
19
<0
Cl
D.M.F.
».2C03
hrs.
Free base
176-177
59.75 5.4 7.55 (59.8 5.2 7.75)
Example No.
R3
Q
! Reaction Solvent
Base
Reaction Tine
Form Isolated n.p.
CC)
Analysis Z (Theoretical In brackets) C H N
JJ
-OEt
EtOH
' -
34 hrs.
Hydrochloride
166-167
36.2 6.15 8.35 (56.25 6.1 8.2)
21
N —J
H
-SMe
EtOH
Et3N
6 hrs.
Acetate
164
55.03 6.15 10.45 (55.9 6.2 10.45)
22
XT
Cl ti-BuOH
4-
diuethyl-
anlno-
pyridlne
18 hrs.
Maleate
2,H2°
156-138
53.9 5.1 8.4 (53.85 5.0 8.3)
23 .
CH, N-4-CH
ll
-SMe
- EtOH
Et3N
1 hr.
Free base
226-228
57.5 6.0 10.8 (57.8 6.0 10.8)
Exaaple No.
R3
Q
ReacCloti Solvent
Base
Reaction Tine
Form Isolated m.p.
(*C>
Analysis Z (Theoretical in brackets) CBN
24
CH,
-i3
h o
-NHN02
n-BuOH
-
18 hrs.
Heni-fuaarste
197-199(d)
56.3 5.4 9.8 (56.4 5.4 9.7)
CONB,
o
-Cl n-BuOH
4-dinethyl-
snlno-
pyridine
18 hrs.
Maleate
163.5-164
56.0 5.1 8.6 (56.1 4.7 8.7)
26
/PH3 S -/A*
-O *
N
-Cl n-BuOH
4-dlnethyl-
amino-
pyridine
24 hrs.
Free base
125
50.1 5.1 9.1 (50.1 5.2 9.3)
27
NH
<s
M mJ
Cl n-BuOH
EtjH
60 hrs.
Tree base Heni-etherate
101-104
57.7 6.2 12.9 (57.9 6.2 13.0)
Exaaple Mo.
R3
Q
Reaction Solvent
Base
Reaction Tine
Fora Isolated n.p.
CC)
Analysis Z (Theoretical in brackets) c h n
28
■Q
cn
-cl n-BuOH
i-dlnethyl-
imlno-
pyrldlne
hra.
• Free base
133-134
58.4 5.2 13.3 (58.7 5.1 13.7)
29
-{3
cokhj
-cl n-BuOH
i-dlnethyl-
anlno-
pyrldlne
4 hrs.
Free base
211
56.5 5.3 13.0 (56.7 5.3 13.2)
.N =\
-cl n-BuOH
4-dlnethyl-
amlno-
pyrldlne
18 hrs.
Ethyl acetate
124-126
57.4 5.8 10.0 (57.8 5.6 10.0)
31
-C$
\-r cl ch2ci2
Et3N
26 hours
Free base
US
55.1 5.1 10.6 (55.3 5.0 10.75)
32
Cl cl
EtOH
etjn
18 hours
Free base
110
55.4 5.35 10.4 (55.3 S.O 10.75)
Exaapla Ho.
R1
q
Reaction Solvent
Base faction i Tl*fi i— —1
Isolated a.p.
CP)
-
Analysis I (Theoretical in brackets) CHS
33
Cl
EtOH
EtjH
18 hour*
ftn twi
142-144
55.3 4.9 10.6 (55.3 5.0 10.75)
34
a%C3
'^N'^SXS)CH3
Cl
BuOH
4-Dloethyl amino pyridine
18 hours
Free base
172-173
58.4 5.8 11.5 (58.9 5.6 11.4)
o^'
Cl
BuOH .
Et3N
48 hours
Free ^sse
165-168
53.5 5.25 9.8 (53.1 5.2 9.9)
36
^^02{J-CH(
Cl
EtOH
EtjH
60 hours
Healhydrate
165-167
53.9 5.5 10.75 (53.8 5.6 10.45)
EXAMPLES 37-57
The following compounds were prepared similarly to Exaaple 8, i.e. by the following reaction:-
and were characterised in the form indicated:-
Example No.
R3
Q
Reaction Solvent
Base
Reaction Time
Form Isolated m.p.
co
Analysis Z (Theoretical In brackets) C H . N
37
N -v,
H
-SMe
EtOH
EtjN
3 hrs.
Hemlhydrate
218 (d)
51.7 5.0 10.3 (51.7 5.1 10.5)
38
7>
-cfr
H 0
-SMe
EtOH
EtjN
22 hrs.
Free base
225-227
53.2 5.4 10.0 (53.4 5.6 10.0)
39
o
H 0
-SMe
EtOH
Et3N
24 hrs.
Hemihydrate
142-145
52.5 4.7 10.4 (52.7 5.0 10.3)
40
-Lj i
-Cl n-BuOH
Et3N
36 hrs.
Free base
179
53.5 5.2 13.0 (53.7 5.1 13.1)
Exaapla Mo.
R3
Q
Reaction Solvent
Base
Reaction Tiae
Font Isolated a.p.
CC)
Analysis Z (Theoretical in brackets) C H M
41
—4 NB
-Cl n-BuOH-
l-diaethyl-
uaino-
pyrldlne
hra.
Free base heml-bydrate
132-134
52.9 4.8 10.5 (52.75 5.0 10.3)
42
B O
-NHN02
n-BuOH
-
18 hra.
Fumarate
144-146
52.4 4.9 8.6 (52.2 4.8 8.4)
43
T°
-NHNO2
BuOH
-
18 hours
Free base
201
56.3 4.7 7.7 (56.0 4.8 8.1)
44
1
ky»
V»
L_ J
-KHNO2
BuOH
-
18 hours
Free baae
205-206
56.65 4.9 11.0 (56.7 4.8 11.4)
Exaaple No.
R3
<1
Reaction Solvent
Base
Reaction Tine
Font Isolated
Iftepe
CC)
Analysis Z (Theoretical In brackets) C H N
45
0""0
Cl
BuOH
EtjN
L8 hours
Free base
177.5-178.5
51.7 5.1 8.5 (52.0 5.1 8.4)
46
O"0
Cl
BuOH
4-Dimetbyl amino pyridine
32 hours
Sesqul-hydrate
182-183.5
51.7 5.3 7.9 (51.9 5.7 8.1)
47
CT"
Cl
EtOH
EtjH
66 hours
Free base
101-104
51.55 5.3 9.0 (51.7 5.1 9.0)
48
Cl
BuOH
4-Dlaethji amino pyridine
18 hours
Free base
190
55.6 5.2 10.6 (55.7 5.15 10.8)
49
clI»
Cl
EtOH
EtjM
18 hours
Free base
101-103
55.2 4.6 9.00 (55.5 5.0 9.25)
Exaaple Mo.
R3
Q
Reaction Solvent
Base
Reaction Tine
Fora Isolated -
n.p.
CC)
Analysis Z (Theoretical In brackets) C H N
50
O
f
X)
Cl
EtOH
Et3N
17 hours
Free base
148-150
53.5 (53.6
.0 4.9
.4 10.4)
51
'TO
Cl
EtOH
EtjH
18 hours
Free base
111-112
51.6 (51.9
4.3 4.5
.2 10.1)
52
XX
Cl
EtOH
Et3N .
18 hours
Free base
113-115
51.8 (51.9
4.6 4.5
.0 10.1)
53
£
Cl
EtOH
EtjH
4 hours
Free base
110
51.7 (51.9
4.5 4.5
9.9 10.1)
1
1
!
1 .
I «
H^N
^O^OCH3
Cl
BuOH
EtjK
48 hours
Free base
162-164
56.8 (57.0
4.8 5.3
9.2 9.2)
Example No.
R3
Q
Reaction Solvent
Base
Reaction Time
Fora Isolated m.p. <*C)
Analysis X (Theoretical In brackets) C H N
55
N -
kjjt
3
Cl
BuOH
Et3N
hours
Free base
146-148
58.4 5.0 9.3 (58.7 4.9 9.1)
56
o
Cl
BuOH
Et3H
7 hours
Free base
158-160
55.5 5.0 10.9 (55.3 5.0 10.75)
57
JvA
OiPr
Cl
BuOH
EtjN
17 hours
Free base
137-139
55.8 5.7 9.8 (56.0 5.6 9.7)
EXAMPLES 58-63
Tha following conpounda were prepared similarly to Exaaple 8, I.e. by the following reaction:-
and were characterised In the form Indicated:"
Example
No.
58
R3
Q
Reaction Solvent
Base
Reaction. Tine
Form Isolated m.p. • CC)
Analysis X (Theoretical in brackets) c h H
-SMe
EtOH
Et3N
4 hours
Hemlhydrate
206-208
50.4 4.7 9.7 (50.75 4.8 9.9)
59
-Q
-SMe
EtOH
-
24 hours
Free Base
139-140
52.6 4.6 9.85 (52.6 4.6 9.8)
60
-&
-Cl n-BuOH
4-diaethyl-
amino-
pyrldlnc
24 hrs.
Free Base
135-136
52.3 4.6 9.7 (52.6 4.6 9.8)
61
<?
B 0
-nh.no2
n-BuOH
-
18 hours
Free Base
147-149
53.5 5.2 9.4 (53.4 4.8 9.6)
Example No.
R3
Q
Reaction Solvent
- Base
Rasctlon Time
Fora Isolated m.p.
C C)
Analysis Z .(Theoretical in brackets) C H H
62
b
-Ska n-BuOH
-
72 hours.
Free Base
128-130
52.2 (52.6
4.7 4.6
9.9 9.8)
63
jCT
-Cl
IMF
-
- 24 hours
HCl.ldljO
175
50.4 (50.5
4.5 4.7
8.2 8.7)
£
EXAMPLE 64
3- ^2-[(4- ^2,3-DichXorophenvl^ -3-ethoxycarbonyl-5-««thoxy-carbonvl-6-methy 1-1.4-dlhydropTrld-2-yl)methoxy ] ethy laalno^ -ae thory-1. 2.5-thladla«ole-l-oxlde
HaOOC
2-[2-ABlnoetlioxyaethyl]-3-ethoxycarbonyl-4-(2,3-dichloro-phenylO-S-wethoxycarbonyl-^-isathyl-l^-dihydropyridirie (0.5 g) and 3,4-dlaathoxy-l,2,5-thladla»ole-l-oxide (0.2 g) were dissolved In 10 methanol (15 al) and heated at reflux for 14 hours. The solvent was evaporated and the residue chrooatographed on silica "Kleaelgel 60H" (Trade Mark), elutlng with ethyl acetate. The product-containing fractions ware combined and evaporated to give an oil which was triturated In ethyl acetate to give the title 15 compound as a solid, yield 0.14 g, m.p. 183-185°.
Analysis I:-
Found: 0,48.1; H,4.6; N.9.4
Calculated £or C^H^Cl^OjS:C,48.15; H.4.55; K.9.75.
EXAMPLE 65
The following compound, m.p. 158-160*, was prepared similarly to the previous Example, starting from the corresponding 4— (2— c±aorophenyl )-lf4-dlhydropyrldlne and 3,4-dlmethoxy-l,2,5-thladiazole-l-oxide. The reaction time was 18 hours, and the solvent methanol:-
Analysis Zi-
Found: C.52.0; H.5.4; N.10.1;
Calculated for C23H27C1N407S: C.51.25; H.5.0; N.10.4.
EXAMPLE 66
The following compound, m.p. 139-141°, was prepared similarly to Example 64, starting from the corresponding 4-(2-chloro-3-trifluoromethylphenyl)-l,4-dlhydropyrldlne and 3,4-dimethoxy-1,2,5-thiadlazole-l-oxide. The reaction time was 18 hours, and the solvent methanol:-
chjooc
CH,
Analysis
?ound! C.47.3; H,4.4; N,9.4
Calculated for C24H26C1F3N407S: C.47.S; H.4.3; N.9.2.
EXAMPLE 67
3-^2-1 (4-fe.3-Dlchlorophenyl^-3-ethoxycarbonyl-5-ii«thoxycarbonyl-6-methyl-1.4-dlhydropyrld-2-yl)«iethoxylethylamlno^ -4-aMino-1.2.5-thladlazole-l-oxld« healhvdrate .
MeOOC
3-^-2-[ (4- £2,3-Dlchlorophenyl$ -3-«thoxycarbonyl-5--m«thoxy-
c«rbonyl-6-methyl-l.4-dihydropyrid-2-yl)Bethoxy ]athylaoino^ -4-aethoxy-l,2,5-thladlacola-l-oxlde (0.3 g) vii dissolved la ethanollc ammonia (10 al) and stirred at rooa teaperature for 1 5 hour. The solvent was evaporated and the residue chroaatographed on silica "Kleselgel 60H" (Trade Mark), eluting with ethyl acetate. The product containing fractions were combined and evaporated to give an oil which was triturated with ethyl acetate to give the title compound as a solid, yield 0.15 g. a.p. 135*.
Analysis t:-
Found: C.46.6; H.4.6; 11,12.1
Calculated for C22H25C128506S•'4B20: C.46.6; H.4.6; H.12.3.
EXAMPLE,68
The following compound, a.p. 130*. was prepared similarly to 15 the previous Exaaple, starting from the corresponding
2-chloropheoyl coapound and aanonla/EtOH. The reaction tine was 1.5 hours:-
B
H
Analysis I:-
Found: C.50.4; H.5.3; H.13.3
Calculated for C22H26C1SS06S: C.50.4; H.5.0; H.13.4.
EXAMPLE 69
3 -The following compound, a.p. 142-145°, was prepared similarly
Co Exaaple 67, starting from the corresponding 2-chloro-3-trlfluorapetbylpheayl compound and asaonia/ethanol. The reaction tlae was one hour:-
Analysis li-Foimd:.
Calculated for C23H25C^r3lf506S: ^2°:
C.45.6; H.4.5; H.11.6; C.46.0; H.4.4; H.11.65.
- 51 -EXAMPLE 70
4-(2-Chlorophenyl)-3-atho3cycarbopyl-5-«ethoxyc«rl>oiiyl-6-methyl-2-[2-(2-thlaiolln-2-ylaalno)ethoxymetliyl1-1.4-dlhydroi>yrldlne
S 2-[2-AminoethoxyBiethyl]-3-ethoxycarbonyl-4-(2-chloro-
phenyl)-5-raethoxycarbonyl-6-methyl-l,4-dihydropyrldine (0.5 g), trlethylamina (0.3 ml) and 2-chloroethyllaothlocyanate (0.16 ml) were dissolved la methylene chloride (5 ml) and the mixture was stirred at room temperature for 2 hours. The mixture was then 10 washed with water (5 ml), dried, filtered and evaporated co give gum. -Chromatography of the gum on silica "Kleselgel 60H" (Trade Mark) elutlng initially with toluene then with chloroform with a trace of methanol gave the title compound, which was recryatalllaad from ether, yield 0.102 g, m.p. 145-147*.
Analysis Z:-
Found: C.55.6; H.5.75; K.8.3
Calculated for C23H28C1B305S: C*55*6: H.5.75; H.8.3.
EXAMPLE 11
4-(2-Chlorophenyl)-3—«thoxycarbonyl-5-iiiethoxycarbonyl-6-netbyl-2-[ 2-(thlazol-2-ylamino) ethwcy—thy 11 -1.4-dlhydropyrldlne
(a) Thlophosgene (0.9 (1) was added to a stirred mixture of 2-(2-aainoethoxymethyl)-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-«et-hoxycarbony1-6-oethy1-1,4-dlhydropyrldlne (4.08 g) and powdered calcium carbonate (3 g) In methylene chloride (25 al) and water (35 ml). The mixture was stirred overnight at room temperature, filtered,, and partitioned between 2H hydrochloric acid and ■ethylene chloride. The organic layer was washed with water, dried; (hjCOj), filtered sad evaporated to give the Intermediate lsothlocyanate as a solid.
This solid was used directly In the next stage of tin reaction without further purification.
(b) The laothlocyanate from part (a) (4 g) vaa heated In ethenollc ammonia solution for 3h hours. The resulting
precipitate was filtered and recrystalllsed from ethanol/methylene : chloride (5:1) to give the Intermediate thiourea, yield 3.8 g, ■.p. 203.5-204.5*.
Analysis I:-
Found: C,53.3; H.5.5; R.8.6
Calculated for Cj^gNjClOjS: C.53.8; H.5.6; N.,8.9.
(c) The thiourea from part (b) (0.2 g) and chloroacetaldehyde (0.1 g) were dissolved la a 1:1 mixture of chloroform/nethanol and the mixture was stirred st room temperature overnight. Removal of the solvent by evaporation left an oil to Which toluene (10 ml)
was added. After removal of the toluene by evaporation the residue was chromatographed on silica ["Kleselgel 6OH" (Trade Mark)]. Elutlon with toluene, ethyl acetate and finally ethyl acetate/IX methanol afforded a white solid which was recrystalllsed from ether to give the title compound, yield 0.075 20 g, m.p. 134*.
Analysis X:-
Found: C.56.0; H.5.4; N.8.4
Calculated for C23H26CU,3°5S: c'56al5> H'5-3I M.8.5.
72-74
The following compounds were prepared similarly Co cha oethod described In part (c) of Che previous Exaaple, scarclng from Che same incensedlate thiourea and, respectively, ClCHjCOCB^, BrCHjCGCOOEt and BrCHjCOOEt.
Example No.
R3
Reaction Solvent
Reaction Time m.p. (*C)
Analysis Z (Theoretical In brackets) C H H
72
ij"3
:1:0.5 CH.G1,: MeuH: Etjti
3 hrs.,
reflux temp.
147*
56.7 5.75 8.05 (56.95 5.6 8.3)
73
N—^COQEt
"< l s JJ
:1:0.5 CHC1.: MeOHT Bt3R
18 hrs..
room temp.
129- ■ 131*
55.3 5.75 7.15 (55.35 5.35 7.45)
74
0
100:1-1
12 hrs.,
room temp.
160-162*
54.1 5.2 8.1 (54.4 5.2 8.3)
EXAMPLE 75
Th« following corpound, a.p. 190-192" was prarparad slallarly to Exaapla 74 but starting from the correapondlng 4- (2-chloro-3H^fluoronethylphemyl) -1,4-dihydropyridLrie and without Isolation of tha laternedlatea. the reaction tlae was 20 hourss-
chjooc
Analysla I;-
Found: C.50.1; H.4.3; H.7.1
Calculated for C^HjjClFjHjOgS: C.50.0; H.4.4; H.7.3.
EXAMPLE 76
Preparation of 4-(2.3-PichlorophanTl)-3-ethoxTcarboBYl-5-aathoxy-carbonv1-6-nathy1-2-[2-(4-oxo-2-thlagolln-2-ylari.no)ethoxv-methy11-1,4-dlhydropyrldlna c°2c2h5
0-«2ch2nh-i 1
- The title conpound. m.p. 204-205°, was praparad by a nethod similar, to that In Exaaple 74 but starting with tha eorraspondlng 4-(2, 3-dlehlorqphenyl) -1, 4 <~dihydropyrldlnft. The reaction conditions 5 were tha saate':-
Analyals t:- '
Found: C.51.2; H.4.7; H.7.7
Calculated for C^H^Cl^OgS: C.50.9; H.4.65; H.7.75.
EXAMPLE 77
4-(2-Chlorophemrl)-3-ethoKTcarbonyl-5-—thorycarbonyl-6-—thyl-2~ [2-(4-[N-»athylc«rbamoyl]-thlazol-2-ylamino)athoxroethy11-1.4-dl-hydropyrid ina
The eater product of Example 73 (0.1 g) was dissolved In a IS 33Z solution of methylamlne In ethanol (10 ml) and the mixture was stood at room temperature overnight and then warmed briefly on a steam bath. Tha solvent was removed by evaporation and the residue chnautographed on silica "Klsaelgel 60H" (Trade Mark). Elution with toluene and then 1:2 toluene/ethyl acetate afforded a
solid which was recrystalllaed from ether to give the title compound, yield 52 mg, n.p. 120*.
Analysis
Found:
Calculated for C^Hj^ClH^OgS:
C.54.35; H.5.3; N.10.2 C.54.7; H.5.3; H.10.2.
EXAMPLE 78
2-12-(4.5-DlhTdro-5-oso-l. 2.4-oxadlazol-3-ylaaino) ethoxyaethyll -4-(2.3-dlchlorophenTl)-3-ethoxycarbonyl--5-iaethoxTcarbonyl-6-methyl-1.4-dlhydroi»yrldlne aonohrdrate
•h2°
H-£2-[4-^2,3-Oichloropheny]J-3-ethoxycarbonyl-5-«ethoxy- : 10 carbonyl-6-methyl-l,4-dihydropyrid-2-yl)i*ethoxy]ethy{|
-N'-cyano-S-methy1-1sothiourea (400 mg) was added to a solution of hydroxylaalne hydrochloride (57 «g) and sodium aathoxlde (44 sg) In methanol (10 al) and heated under reflux for 1 hour. The solution was evaporated to dryness and the residue taken up In 15 ethyl acetate and waahed with 2M hydrochloric acid and aqueous sodlua carbonate. The organic layer was dried over magnesium
sulphata, filtered and evaporated. Tha residue wa« chrooatographad on "Merck" (Trade Mark) J60 silica slating with ethyl acetate. 'The product containing fractions were combined and evaporated to dryness, trituration with ether giving the title 5 compound (70 ng), m.p. 132-134*.
Analysis 88-
Found: 0,48.45; H.4.8; N.10.3
Calculated for C^Hg^CljH^Oj.HjO: C.48.3; H,4.9; N.10.5.
EXAMPLE 79
2- [ 2-(2-Hathyl-3-/3-»»thylureldoV-2H-l. 2.4-tria«ol-5-ylaalno) -ethoxy—thyl ] -4- ( 2.3-dlchlorophenyl) -3-«thMtycarbonyl-5-methoxycarbony1-6-methy1-1.4-dlhydropyridlne hydrate
A solution of (1) (0.2 g; product of Example 9 and methyl 15 isocyanate (0.6 ml) in methylene chloride (50 ml) was stirred at room temperature for 18 hours. The solvent was evaporated to dryness and the residue was chroaatographed on Merck (Trade Mark)
J60 silica elutlng with SZ methanol in methylene chloride. The product-containing fractions were combined and evaporated to . dryness, trituration with ethyl acetate giving the title compound, yield 0.04 g; m.p. 110-112°.
Analysis Z;-
Found: C.51.8; B.5.9; H.16.9
Calculated for C^H^ClHfOg.BjO: C.51.8; H.5.9; N.17.1.
EXAMPLE 80
4-(2,3-Dlchlorophenyl)-3-ethoxycarbonyl-5-aathoxycarbonyl-6— methyl-f2-(6-«orphollnopTrinidin-4-yl«aino)ethoxvmethy1]-1.4-dlhydrowrridlne
3
b b
b
B
. 4-(2,3-Dlchlorophanyl) -3-ethoxycarbonyl-5-»ethoxycarbonyl-6-aethyl-2-[2-(6-chloropyrinldln-4-ylaalno)•thozyaathyl]-1,4-dlhydropyrldlne (0.3 g) (Product of Exaaple S3) end norpholine (S ■1) ware heated together on a ateaa bath for 18 hours. The.excess 5 aorphollne was then evaporated and the residue was taken up In ethyl acetate, filtered and chronatographed on silica "Kleaelgel 6OH" (Trade Mark) elutlng with ethyl acetate. The product-containing fractions were conbined and evaporated to dryness, trituration with ether giving the title cospound (165 10 ag), a.p. 163*.
Analysis I:-
Found: C.55.1; H.5.5; N,11.2
Calculated for CjgH^CljMjOg: C,5S.4S; H.5.5; N,11.55.
EXAMPLES 81-84
The following coapounds were prepared similarly to the previous Exaaple, I.e. by the following.reaction.
and were characterised in the fora Indicated:-
Exaaple Ho.
y
■~y
Reaction Solvent
Reaction Tlae
Form Isolated a.p.
CC)
■ i
Analysis X (Theoretical In brackets) C H H
81
. A ^ VcH
w 3
-
18 hours
Free base
168-170
56.5 5.9 13.4 (56.2 5.9 13.6)
82
-
18 hours
Free base
140-142
57.9 5.7 11.2 (57.6 :5.8 11.6)
83
B
YY^
EtOH
18 hours
Free base
158
54.2 5.2 12.8 (54.55 5.3 12.7)
. 84
J5
CH3
EtOH
. 30 hours
Free base
88-90
54.5 5.55 12.6 (54.55 5.3 12.7)
- 63 -EXAMPLES 85-8.7 The foUcwtng conpounda vara prepared similarly to Example 80, i>a. by the following' reaction
S and were characterised la the fora Indicated:-
Exaaple No.
y
Reaction Solvent
Reaction Time
Form Isolated
D«p»
CC)
Analysis X (Theoretical In brackets) C H N
85
N^H
' -
18 hours
Hydrate
147
59.4 6.4 11.8 (59.2 6.5 11.9)
86
/""\
Y
»v/»
-
hours
Heai-fuaarate Haal-hydrate -
171
56.4 5.8 10.95 (56.3 3.75 U.3)
87
X
0
i i
-
18 hours .
Free base
133-134
58.45 6.0 12.4 (58.8 6.0 12.2)
- 65 -EXAMPLE 88
4-(2-Chloro-3-trlfluoroaethylph«nyl) -3-ethoxycarbonyl-5-mBthogyca-rbonyl-6-aBthvl-[2-(6-iaorphollno-pyrlBldln-4-ylamlno)ethorymethyl-
methoxycarbonyl-6-«athyl-2-[2-(6-chloropyri»idin-4-ylamino)-ethoxynethyl]-l,4-dlhydropyridine was prepared similarly to the procedure of Exaaple 53 from appropriate starting materials and 10 was reacted unpurlfled with aorpholine by a procedure slallar to that of Exaaple 80 to give the title compound, a.p. 117-118*.
Analysis t:-Found:
Calculated for C29H33C1?31,5°6:
C.54.0; B.5.6; 11,10.7 C.54.4; H.5.2; H.10.9Z.
- 66 -EXAMPLE 89
4-( 2.3-Pichloropheny1)-3-ethoxr catbonvl-5-«etho*ycarbowr 1-6-aethy1-2-f2-(pyrazln-2-vlaalno)«thoxy»athyl]-1.4-dlhydropyrldln«
■ethoxycarbtmy 1-6-nethy 1-2- [ 2-(pyra*ln-2-ylamino) athoxystethy 1 ] -1,4-dlhydropyrIdine (0.35 g) (product of Example 50) was haated on a stem bath la 50Z aqueous ethanol (15 ml), to which vaa added 10 sodium dithlonlte (2 g) portlomrlse over 1.5 hours. The reaction mixture was then heated for a further 1.5 hours before the solvent was evaporated and the residue partitioned between ethyl acetate and water. The organic layer was separated, dried, filtered and evaporated to give an oil. Chromatography on silica "Klesgel 60 15 R" (Trade Mark) elutlng with ether gave an oil which afforded the title compound when triturated with dilsopropyl ether, yield 134 sg., a.p. 113*.
a
The N-oxlde of 4-(2,3-dlchlorophenyl)-3-ethosycarbonyl-5-
Analysis Xi-
Found: C.55.2; H.4.9; S.10.6
Calculated Cor C^H^Cl-jH^: C.55.3; H.5.0; H.10.75.
EXAMPLE 90
(A.) Preparation of 4-(2,3-Dlchloroph«py1)-3-«thoxycarbony1-2-I2-(3-ethoxycarbonylthloureldo)athoxyaethyl]-5-«ethoxycarbony 1-6-■ethrl-1. 4-dlhvdropyridlne
To a suspension of 2-(2-amino«thoxyi*ttay1) -4- (2,3-dichloro-pheny1)-3-ethoxycarbonyl-5-nethoxycarbonyl-6-mathyl-l,4-dlhydropyrldlne (4.43 g) In dry chloroform (50 al) was added, dropwlse, s solution of ethoxycarbonylisothlocyanate (1.31 g) in dry chloroform (25 ml). The reaction was stirred for 18 hours at room temperature before. evaporating the solvent and triturating the residue with ether to afford a solid which was recrystalllsed from dilsopropyl ether to give the title coapound, yield 2.6 g, m.pt. 144*.
Analysis
Found: 0(50.6; H,5.2; 8,7.0
C«lcnl«C*d for C24^9C12H307S:.. C.50.2; H.5.1; K.7.3.
(B.) Preparation of 4-(2.3-Dlchlorophenyl)-3-ethoxycarbony1-2-5 [Z- (5-hydroMr-lHrl. 2.4-triazol- 3-y 1 amino ) athoxyne thy 17-5-
tthoxycarbony1-6-methy1-1.4-dlhydropyrldlne hydrate ,ci
1) Mai
To a suspension of 4-(2,3-dlchlorophenyl)-3-ethoxycarboiiyl-2-[2-(3-ethoxycarbonylthloureido)ethoxyaetbyX]-5-methoxycarbony1-6-me thy1-1,4-dlhydropyrldlne (0.25 g) In dry tetrahydrofuran (THF) (5 ml) was added sodium hydride (0.02 g). After stirring for 1 hour at room temperature a solution of methyl Iodide (0.07 g) in dry THP (5 ml) was sdded dropwlse and stirring was continued overnight. After evaporation of the solvent, the residue was taken up In methylene chloride and washed (aqueous NaCl), dried (MgSO^), filtered and evaporated to give a yellow oil (150 mgs).
69 -
Tha oil was dissolved la lsopropanol (5 ml) containing hydrazine hydrate (0.06 g) and heated under reflux for 2 days. Tha solution was than evaporated and tha residue taken up in methylene chloride and washed (aqueous NaHCO^), dried (MgSO^), filtered and 5 evaporated. The residua was then chromatographed on silica
"Kleselgel 60 H" (Trade Mark), elutlng with ethyl acetate/methanol (1Z Increments up to 20Z methanol). Product-containing fractions were combined, evaporated and recrystalllsed from ethyl acetate to afford the title compound, yield 0.048 g, m.pt. 158*.
Analysis Zi-
Foimd: C.48.5; H.4.8; N.13.0
Calculated for C^H^ClglgOf.HgOt C,48.5; H.5.0; N.12.9.,
EXAMPLE 91
(A) Preparation of 4-(2.3-dlchloroi>henyl)-3-athoxy carbony l-2-[ 2-15 (5-hrdro»r-4-metlivlpyrlmldin-2-ylamlno)athoxvsthvH-5-methoCTcarbonv1-6-methy1-1.4-dihydropyridlna
Ms0H/H20
CH.
H
A nlxture of 2-( 2-amino«thoxyiMthyl)-3--«thoxy carbony 1-4-2,3-dichlorophenyl)-5-«athoxycarbony1-6-aethy1-1,4-dihydropyrldine (3.6 g) and 5-acetyl-2-a*ino-oxaxole (0.5 g) in methanol (2 ml) and water (3 nl) was heated on a steam bath for 24 hours. The 5 mixture was then evaporated to dryness and the residue was chroaatographed on silica "Kieselgel 6OH" (Trade Mark) eluging . with ethyl acetate. The product-containing fractions ware combined, evaporated and the residue triturated with ether to give the title compound (0.1 g), m.p. 165*.
Analysis X:-
Found: 0,54.3; H.5.2; H.10.2
Calculated for C25H28C12H4°6: c»54-*5! H.5.1; N.10.2Z.
(B) Preparation of 2-[2-(4-acetylimida»ol-2-Tlamlno)ethoxT-aathTll-4-(2.3-dichlorophenyl)-3-ethoxycarbony1-5-methoxv-15 carbonYl-6-nethy1-1.4-dihydropyrIdlne chjojc
-Cl:
Me0H/Hz0
Froa che same reaction deacrlbad in Part (A) a aecond, aore polar product was subsequently eluted froa tha cbroaatography coluan using echyl acecace as the elueut. The fractions containing chla second produce were combined, evaporated and the S residue waa redlasolved in Methylene chloride, washed with dlluce hydrochloric add than with aqueous sodlua bicarbonate, dried (MgSO^), filtered and evaporated. The realdue waa recryacalllsed froa echyl aceCaCe Co give Che cltle compound (0.14 g), a.p. 177*.
Analyals I:-
Founds C.54.6; H.5.5; H.9.9
Calculated for C25H28C12H4°6: c,54-*5» B>s-1> H.1Q.2Z.
examples 92-97
The following compounds were prepared similarly to the procedure of Exaaple 8, I.e., by Che following reactIon:-
c2h5ooc ch.
3
3
2
-f
C2H5OOC
ch.
3 m h nh.r
3
H
Ex aspic No.
R3
Q
Reaction Solvent
Base
Reactlotk . Tine
Fora Isolated
D«Pe
<*c)
Anelysls X (Theoretical in brackets) CBN
92
-fi
H\,_r
Cl nBuOH
4-dinethyl-
amino pyridine
24 hrs.
Free bsse hemi-hydrate
139-141
53.15 5.1 10.6 (52.75 5.0 10.25)
93
-Q
0
Cl nBuOB
EtjH
33 hours
Hemi-funarate
197-199
52.4 4.9 9.3 (52.4 A.7 9.4)
94
H 0
-NHN02
EtOH
18 hours
Free base sesqui-hydratc
222
51.6 5.4 9.7 (51.9 5.4 9.4)
95
<5
H 0
-SMe
StOB
-
18 hours
Hydrochlorid)
203-205
50.0 4.9 9.9 (50.2 4.7 9.8)
Exaaple No.
1
I I
! ! 1 n«
I : ■
i i i i
<2
Reaction Solvent
Baae
Reaction Tine
Fora Isolated a.p.
rc>
Analysis Z (Theoretical in br'ackata) C H N
96
-CV
H
-SMe
EtOH
Et3N
17 hours
Hydrochloride head-hydrate
195-198
48.5 4.8 9.85 (48.3 4.9 9.8)
97
^ Cl
-ty
-Cl
EtOH
EtjN
50 hours
Free base
153
51.8 4.6 9.95 (51.9 4;5 10.1)
EXAMPLES 98-102 Tha following conpounda ware prepared 8lnllarly to the procedure of the stated Example.from appropriate starting materials
CjUJOOC
Example No.
Prepared slaillarly Co che procedure of Example no.
*3
m.p.
(*C)
Form Isolated
Analysis X (Theoreclcal in brackecs) C H N
98
74
H 0
194-196
Free base
50;7 4.8 7.7 (50.9 4.65 7.75)
99
80
rvO
Nn^M
167-169
Free base
55.5 5.6 11.4 (55.45 5.5 11.55)
100
1
XT'
h
173-
"5
Free baae hemi-hydrate
49.3 5.05 15.5 (49.4 5.1 15.7)
101
64
Tf
N Vg-N
if n
138-140
Free baae
48.1 4.9 9.7 (48.2 4.6 9.8)
102
67
^NH_
142-144
Free baae hemi-hydrace
46.35 4.9 12.3 (46.6 4.6 12.3) .
Tha following Preparations Illustrate the preparation of certain starting materials. All temperatures are In *C:-
Prepqratltm 1
Preparation of 2-[(2-amlnoethoxy)nathyl]-4-(2-chlorophauTl)-3-ethoxy carbony l-5-«thoxycarbony 1-6-iMthy 1-1.4-dlhydropyrldlne maleate
A suspension of 2-(2-asidoethoxy*ethyl)-4-(2-chloroptaanyl)-3-ethoxycarbony1-5-nethoxycarbony1-6-iwthyl-1,4-dlhydropyrldlne (103 g) In ethanol (2.5 1) was stirred for 16 hours at room temperature under one atmosphere of hydrogen In the presence of 5Z palladium on calcium carbonate (40 g). The reaction mixture was filtered and evaporated and the residue treated with a solution of malelc add (22 g) In ethanol (100 ml). The reaction mixture was stirred at roam temperature for 2 hours and then tha resulting solid collected, washed with ethanol, and dried to give the title compound (100 g), m.p. 169-170.5".
Analysis Z;-Found: .
C24H29C1H209 t*«Ittlt*8S
C.S4.82; H.5.62; H.5.46 C.54.91; B.5.S7; H.5.34.
Preparation 2
2- [ 2-Amino«thoxymethyl] -4-[ 2,3-dichlorophenyl] -3-ethoxy-
carbonyl-5-«iethoxy carbony l-6-»athy 1-1,4-dihydropyridine, a.p. 171-3", waa prepared similarly co Che previous Preparaclon Croat che appropriate axldo compound, and waa characterised as Che hcalfuaaraCe hemihydrata.
Analysis 8;-
Found: 'C.51.7; 11,5.3; H.5.5
Calculated Cor C^H^CljHjOj.Jtf^H^.lsHjO: C.51.8; H.5.3; H.5.5
Tha heaifuaarate was neutralised to the free base Cora, a.p.
120-122*.
Preparation 3
2-(2-Aaldoethoxymathyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbony1-6-methy1-1.4-dlhydropyrldinc
. A solution of 2-azldoethanol (160 g) in tetrahydrofuran (300
al) was added over 40 minutes Co a suspenalon of sodlua hydride (114 g; BOX dispersion In oil) in CeCrahydrofuran (500 ml). The alxcure was stirred aC room ceaperature for 1 hour and che Ice-cooled soludon CresCed vlch a solution of ethyl.
4-chloroacetoacetate (276 g) In tetrahydrofuran (250 al) dropwlae ovar 2 hour*. The aixture waa stirred at rooa temperature for 16 hours, diluted with ethanol (150 al), and the pH adjusted to 6-7 with 4M hydrochloric add. Sufficient water was added to dissolve 5 the solid present and the layers were separated. The organic layer was evaporated and the residue diluted with water (600 al) and evaporated. The residue was partitioned between ethyl acetate and water and the aqueous layer extracted twice with ethyl acetate, the conbined ethyl acetate extracts were dried (MgSO^) 10 and evaporated to give ethyl 4-(2-azidoethoxy)acetoacetate as a brown oil. which was shown by g.l.c. to be 73X pure. A aixture of this crude product and aanonlua acetate (92.3 g) in ethanol (600 al) was heated under reflux for 1 hour, allowed to cool to rooa temperature, and treated with methyl 2-(2-chlorobenzylldene) 15 acetoacetate (286.6 g). The atxtur* was heated under reflux for . 5.5 hours and then evaporated. The residue was stirred with aethanol (1.5 1) for 16 hours and the resulting solid collected, washed twice with aethanol, dried, end recrystalllsed froa aethanol to give the title coapound (78. g), a.p. 145-146°.
Analysis X;-
Found: C.55.39; H.5.37; 11,13.01
Calculated for C^H^CIN^: C.55.23; H.5.33; N,12.88.
Preparation 4
2-(2-Asidoethoxy)aethy1-4-(2,3-dichlorophenyl)-3-ethoxyr 25 carbonyl-5-*«thoxycarbony1-6-methy1-1,4-dihydropyrine was prepared by the aethod described In Preparation 3 using oethyl
2-(2,3-dlchlorobenzylidene)acetoaeetata Instead of methyl 2-(2-chlorobenzylldene)acetoacetate. The product had an a.p. of 141°.
Analysis
Found: C,50.88; H.4.78; 8,11.73
Calculated for c2oH22C12H405: c,51-18; H.4.73; M.11.94.
Preparation 5
(1) Preparation of Bthyl-4-(2-phthallmidoethoxy)acetoacatato j*?'.. -wfjg)
o
To a slurry of sodlua hydride (57Z dispersion in oil, 66.1 g 1.57 M), In tetrahydrofuran (500 ml) cooled to 0* under nitrogen waa added 2-phthallnldoethanol (150 g; 0.785 M) followed by ethyl 4-chloroacecoacetate (129 g; 0.785 M) In tetrahydrofuran (250 al) over 1 hour. The mixture was stirred at room temperature overnight then poured Into a mixture of 1M hydrochloric acid (800 ml) and ethyl acetate (750 ml). The organic phase was separated, and the solvent was evaporated at reduced pressure. The residue separated Into two layers and the upper layer of mineral oil was removed to leave the title compound (243 g) as a crude product which was used without further purification.
(11) Preparation of 4-(2-chlorophenyl)-3-gthoxycarbony1-5-methosycarbony1-6-methy1-2-t2-phthallaldoathoxyinathyl] -1,4-
Methyl 3-aalnocrotonats (72.2 g; 0.627 M) and 2-chlorobenzaldehyde (88.1 g; 0.627 M) were added co a solution of ethyl 4-(2~phthalimidoethoxy)acetoacetate (200 g; 0.627 M) in lsopropanol (1 litre) and the mixture was heated under reflux for 20 hours. The lsopropanol was evaporated under reduced pressure and replaced by acetic acid (1 litre). After granulation at 10* the solid was collected end slurried In methanol (300 ml). The solid ns collected by filtration and dried In vacuo at 50* to afford the title compound, yield 84.4 g, m.p. 146-147*.
Analysis I:-
Found: C.62.2; H.5.0; N,5.2
Calculated for CjgH^ClK^: C.62.4; H.5.05; H,5.2.
dlhydropyrldlne o
• o
Preparation 6
The following conpound, n.p. 148-150*, waa prepared similarly to the previous Freperatlon hut ualng the correapondlng 2,3-dlchlorobenzaldehyde. The reaction time waa the aame:-
Analyala Zi-
Found: C.58.7; H.4.5; H.5.0
Calculated for C2gH26Cl2N207: C.58.6; H.4.6; N.4.9.
- 82 -Preparation 7
Preparation of 2-(2-amlnoethoryaethyl)-4-(2-chlorophenyl)-3-etho3rrcarbonyl-5-«iethoxTcarbonyl-6-methvl-l .4
meojc
Tha intermediate phthallaldo compound from Preparation 5 (400 g) waa suspended in ethanol (6 litres) containing hydrazine hydrate (111 g) and heated under reflux for 2 hours. After cooling the reaction mixture was filtered and the filtrate was evaporated to give a yellow oil. The oil was taken up In methylene chloride (6.5 litres)> washed (HjO), dried (MgSO^) and evaporated. The residue waa taken up In hot methylated spirit (1.2 litres) and diluted with hot methylated spirit (400 ml) containing maleic acid (86 g). After cooling the title compound crystalliaed out as ita maleate aalt, yield 303 g, m.p. 169-171*.
Analysis Z:-Found:
Calculated for CjqHjjClUjOj.C^H^O^:
C.54.8; H.5.55; N.5.3 C.54.9; H.5.6; H.5.3.
- 83 -Preparation 8
The following compound, m.p. 171-173* waa prepared similarly to the previous Preparation but starting froa the corresponding 2,3-dichlorophenyl compound:-
NHjr Fuaarate, *i H^O.
Analysis X:-
Found: C.51.55; H.5.3; H.5.4
Calculated for c2oH24Cl2H2°5*C4H4°4'l,H20: c'51*5: H.5.05; H.5.O.
PREPARATION 9
The following compound, a.p. 179*, was prepared similarly to
Preparation 5 but using the corresponding 2-chloro-3-trifluoromatfaylb«nzaldehyde in stage (ii). The reaction.tine was the same:- .
Anilwtl Xi-
Fotmd: C.57.2; H.4.45; H.4.8
CalcuUted for C29H26CUr3N207: . C.57.4; H.4.3; H.4.6.
PKEPABATION 10
Preparation of 2-(2-Azldoethoxymethyl)-4-(2-chloro-3-trl.fluoro-aethylpheny 1) -3-«thoxycarbopyl-5-irathoxycarbonyl-6-iiathyl-l. 4-dihydropyrldine ch302c>s<f^s^c02c2h5
chf^n— ch20ch20h2h3
The title compound, a.p. 143-145*. was prepared similarly to the method described In Preparation 3 but using the corresponding 2-chloro-3-trlfluoromethylbentaldehyde. The reaction time was che same:- .
Analysis X:-
Found: C.50.2; H.4.4; N.11.3
CalcuUted for C21H22C1F3H405: C.50.15; H.4.4; H.ll.l.
- 85 -Preparation 11
Preparation of 2-f 2-AmlnoathoxYgathyll -4-(2-chloro-3-trlfluoro-awthylphenyl)-3-athoxycarbony1-5-aathoxycarbony1-6-gethyl-1,4-dihydropyrldlne
®302c>;^vc02c2h5
ch2och2ch2nh2
h
The title compound was prepared by the catalytic hydrogenatlon of the asldo compound of Preparation 10 by the method described In Preparation 1. This compound was confirmed by n.m.r. and i.r. analysis to be identical to the product of 10 Preparation 13.
Preparation 12
Preparation of 2-(2-A»ldoetho*ymethyl)-4-(2.3-dlchlorophenyl)-3-aethoxycarbonyl-5-ethoxvcarbonyl-6-«ethyl-l.A-dlhydropyrldlne
H5C2°2C
2-o-ch2ch2n3
The title compound, a.p. 126°, was prepared similarly to the method described In Preparation 3 but using methyl 4-bromoacetoacetate Instead of ethyl 4-chloroacetoacetate yielding methyl 4-(2-asidoethoxy)acetoacetate instead of ethyl 5 4-(2-axldoethoxjscetoacatata. The other conditions were the
Analysis Xt-
Pound: GiH,4»7, Nf12*lt
Calculated for c2oH22C121,405: C' 51-2» H'4-7' «.U.9.
1° Preparation 13
Preparation of 2-(2-amlnoethoxymethTl)-4-(2-chloro-3-trifluoro-
»ethvlphenv1)-3-«thoxy carbony1-5-gethoxycarbonyj-6-methyl-l. 4-dlhydropyrldlne
Aqueous CH^NHj
,cooc2hs
The intermediate phthallaido compound froa Freperatlon 9 (2.8
g) was added to aqueous Bethylmnine (14 al of 40Z) end stirred at rooa temperature for 17 hours. The resultant solid was filtered,
redlssolved In chloroform (50 al), dried (MgSO^), filtered and
evaporated to give a yellow solid. Crystallisation froa hexane gave the title compound, yield 1.0 g, a.p. 122*.
Hie title compound is the subject of Patent Specification
NO. ; . .. ; .
Analysis X:-
Found: C.53.25; H.4.9; N.5.75
Calculated for Cgji^ClF^Oj: C.52.9; H.S.I; 11,5.9.
Preparation 14
Preparation of 4-(2.3-dlchlorophenTl)-5-ethoacTcarbonyl-3-aethoxvcarbony1-6-aethy 1—2—12-phthaliaidoethoirvaethylI -1.4-15 dihydropyrldlne c^hjooc co2ch3
n'1 ch20ch2ch2h
H
The title coapound, a.p. 165*, was prepared slalla'rly to the method described in Preparation 5(11) but using 2,3-dichloro-benzaldehyde, methyl 4-(2-phthaliaidoethoxy)-acetoacetate and ethyl 3-aalnocrotonate.' The reaction time was the sane:-
Analysis I:-
Found: C.58.5; H.4.7; H.5.0
Calculated for. CjgHjjCljH^s C.5&-65; H.4.6; H.4.9.
The starting acetoacetate was prepared similarly to 5 Preparation 3(1).
Preparation 15
Preparation of 7-^7-»iilno«thoxyBBthyl)-4-(2.3-dlchloroph«nyl)-5-ethoxycarbony l-3-«ethoxy carbony 1-6-methyl-l ,4-dUiydropyridine
The title compound, a.p. 131-132°, was prepared similarly to the method described In Preparation 13 but using the material from Preparation 14.
Analysis Found:
Calculated for C2oH24C12N2°5:
C.53.9; H.5.5; H.6.4 C.54.2; H.5.5; H.6.3.
Preparation 16 . Preparation ot 2-chloro-3-trifluoroi»athvlbengaldehyda
2-Chloro-l-trifluoromethyJ.benzene (54.15 g) waa dissolved la dry tetrahydrofuran (500 al) and stirred while cooling to -68* under a strew of dry nitrogen. (The whole reaction Is carried out under dry nitrogen until the addition of distilled water.). To this was added n-butyl lithium (180 ml of a 1.6 M solution In hexane) dropwlse keeping the temperature below -60*. 'After stirring at -68* for a further 2 hours, a solution of dlmethylfoxmsmlde (22 ml) In dry tetrahydrofuran (100 ml) waa added dropwlse keeping the temperature below -60*. The reaction mixture was allowed to warm to room temperature slowly over 17 hours and distilled water (200 ml) was then added. The organic phase waa .separated off and the aqueous liquors were extracted with ether (100 ml). The combined ether extracts plus the organic phase ware washed with saturated brine, dried (MgSO^), filtered and evaporated to give 61.5 g of an orange oil, being the crude title compound.
This oil was then added to an aqueous sodium bisulphite solution (65 g in 600 ml distilled water) and heated at - 60* for 0.5 hours. The solution was extracted with methylene chloride (3 x 100 ml) and, after acidification of the aqueous phase with concentrated sulphuric acid to pHl, was heated at 100* for a further 0.5 hours. The resultant aqueous solution was extracted with methylene chloride (3 x 200 ml) and the combined organic. extracts were dried (MgSO^), filtered and evaporated to give 42 g of a colourless solid Mich was crystallised from hexane to give the title compound, m.p. 43-44*.
Analysis X:-
Found: C.45.9; E.2.0
Calculated for CgH^FjClO: C.46.1; H,2.0.
Preparation 17 %
Preparation of 2.3-d ichlorobenzaldehyde
A similar route to that described In the previous g
Preparation, starting from 1.2-dlchlorobenzene, proved to be a superior method for preparing the title compound, m.p. 62*.
Analysis X:-
Xo Found: C.47.62; H.2.38
Calculated for CjH^Cl^O: C.48.04; H.2.30.
Activity Data
The molar concentrations of the compounds required to reduce the response by SOX In the test specified on pages 16-17 are given below (1M " 1 gm.Kole/Utre). The smaller the concentration the more active the compound.
Compound
i£so
Product of Example
IB
2
X
io-8
N
Product of Example
2
2.29
X
"9
M
Product of Example
3B
6.02
X
"9
M
Product of Example
4
8.12
X
~9
M
Product of Example
3.02
X
io~9
M
f
(
Coapound
Product of Exaaple 6 Product of Example.7 Product of Example 8 Product of Example 9 Product of Exemple 10 Product of Example 11 Product of Example 12 Product of Example 13 Product of Example 14 Product of Example 15 Product of Example 16 Product of Example 17 Product of Example 18 Product of Example 19 Product of Example 20 Product of Example 21 Product of Example 22 Product of Example 23 Product of Example 24 Product of Example 25 Product of Example 26 Product of Example 27 Product of Example 28 Product of Example 29 Product of Example 30 Product of Example 31
i£so
1.15
X
IO-8
M
3.47
X
"9
M
1.05
X
io"8
M
1.26
X
-®
M
1.9
X
IO"9
M
4.26
X
IO"7
M
2.88
X
IO"*
M
6.3
X
IO'9
M
_8
1.0
X
M
.01
X
io-®
M
1.00
X
IO"7
M
1.31
X
IO"8
M
3.16
X
"8
M
1.00
X
IO"8
M
1.00
X
IO"7
M
1.00
X
IO"7
H
1.82
X
IO"8
M
1.00
X
ID"7
M
1.00
X
IO"8
M
4.57
X
IO-8
M
3.71
X
io-9
K
3.98
X
io-9
M
1.31
X
IO-8
M
1.81
X
io-8
K
2.34
X
"9
M
1.77
X
-8
M
Compound IC,
Product of
Exaaple
32
1.58
X
"°
M
Product of
Exaaple
33
6.30
X
io-9
M
Product of
Exaaple
34
1.31
X
io-8
M
Product of
Example
.75
X
IO"9
M
Product of
Exaaple
36
3.16
X
"9
M
Product of
Exaaple
37
1.00
X
IO-8
M
Product of
Exaaple
38
2.51
X
IO-8
M
Product of
Exaaple
39
2.69
X
-9
M
Product of
Example
40
2.23
X
~9
M
Product of
Example
41
7.76
X
IO"10 M
Product of
Example
42
4.16
X
-9
K
Product of
Exaaple
43
8.31
X
~9
M
Product of
Exaaple
44
1.58
X
IO"8
M
Product of
Exaaple
45
1.09
X
-9
M
Product of
Exaaple
46
3.01
X
io-9
M
Product of
Example
47
1.25
X
io"9
M
Product of
Example
48
2.95
X
IO-8
M
Product of
Example
49
3.98
X
IO-9
K
Product of
Example
50
1.34
X
io-9
M
Product of
Example
51
2.51
X
IO-9
M
Product of
Exaaple
52
6.02
X
IO-9
M
Product of
Example
53
3.16
X
IO"6
M
Product of
Example
54
1.20
X
io"9
M
Product of
Example
59
3.72
X
IO"9
M
Product of
Example
60
4.47
X
IO"8
M
Product of
Exemple
61
2.24
X
io-9
M
"93
Cunuound
^£50
Product of
Exaapla
62
1.35
X
IO'9
M
product of bnflt
63
.. 2.95
X
IO-9
M
Product of
Exaaple
64
1.00
z
IO"8
M
Product of
Exaaple
65
2.51
X
IO"8
M
product of
Exaaple
66
2.24
X
-9
M
product of
Exaaple
67
1.99
X
"8
M
Product of
68
1.31
X
io-8
M
Product of
Exaaple
70
9.33
X
"9
M
Product of
Exaaple
71
1.00
X
"8
M
Product of
Exaaple
72
3.98
X
"®
M
product of
Exaaple
73
4.4
X
io"9
M
Product of
Exaaple
74
2.00
X
"8
M
Product of
Exaaple
75
7.08
X
-9
*M
product of
Exaaple
77
.37
X
-9
M
Product of
Exaaple
78
2.29
X
-9
M
Product of
Exeaple
79
6.60
X
-9
M
Product of
Exaaple
80
1.34
X
-9
H
Product of
Example
81
3.16
X
-9
M
Product of
Exaaple
82
4.07
X
-9
M
Product of
Exaaple
83
3.16
X
-9
M
Product of
Exaaple
84
.01
X
-9
M
Product of
Exaaple
85
.01
X
-9
M
Product of
Exaaple
86
1.58
X
-9
M
Product of
Exaaple
87
1.00
X
-7
M
Product of
Exaaple
88
1.26
X
io"10 M
Conpound Zko
Product of Exaaple 89 5.01 x 10~*" M
Product of Exaaple 90B ,1.00 x IO-8 M
Product of Exaaple 91A 1.00 x 10-' M
Product of Exaaple 9IB 2.5 x M
Claims (23)
1. . A d ihydropyrid J ne of tho formula:- 1 2 r ooc coor I I (I) 3 ci«3 N cii2-o-*-ni« or a pharmaceutlcally acceptable acid addition salt thereof; 5 wherein R is a phenyl group optionally substituted by one or two substltuents each Independently selected from nltro, halo, Cj-C^ . alkyl, Cj-C^ alkoxy, hydroxy, trlfluoromethyl, and cyano; 1 2 R and R are each Independently C^-C^ alkyl or 2-methoxyethy1; 10 Y Is -(CH2)2-; 3 R Is attached to the adjacent nitrogen atom by a carbon atom and Is either (n) » monocyclic 5- or 6-mombcred heterocycle containing at least one N atom and optionally one or two further lieteroatoms or groups each Independently selected from 0 0 * t 0, S, S, N and N, and Is optionally substituted by Cj-C^ alkyl, Cj-C^ alkoxy, halo, hydroxy, oxo, cyano, 3-(Cj-C^ alkyl)ureido, 4 5 phenyl, phenoxy, pyridyl, acetyl, (C^-C^ alkoxy)carbonyl, -NR R , -S02NR4R5 or -CONR^R^ where either R^ and R^ are each 4 5 Independently II or flJkyl or K and K together with the 20 - 96 - nitrogen .-itom to which they nrc nttoclicil represent a saturated 5-or 6-membered heterocyclic group optloually containing a further heteroatom or group selected from 0, S, NH. H(Cj-C^ alkyl) and NCI10; or (b) a blcycllc group which Is an optionally substituted 5 S- or 6-membered heterocycle as defined In (a) fused to an imidazole or benzene ring, said benzene ring being optionally . substituted by Cj-C^ nlkyJ, C^-C^ alkoxy or halo.
2. A compound as claimed in claim 1 wherein R la a phenyl group substituted by 1. or 2 substltuents selected from halo and 10 CFy
3. A compound as claimed In claim 2, wherein R is 2-chlorophenyl, 2,3-dlchloropheny] or 2-chloro-3-trifluoro-metliylplieny I.
4. A compound as claimed In any one of the preceding claims 15 wherein either (a) R1 Is Cllj and R^ Is C^Hj or (b) R^ is CH^ and R1 Is CjHj.
5. A compound as claimed lu any one of the preceding claims . 3 wherein R is a heterocyclic group selected from trlazolyl, oxadi'azoly], pyrimldlnyl or a partially saturated derivative 20 thereof, purlnyl, quinazollnyl, lmldazolyl, imldazollnyl, trlazlnyl, pyridyl, thlazolyl, thlazollnyl, benzthlazolyl, thladlazolyl, pyrazlnyl, qulnoxallnyl and pyrrollnyl, and their N-and S-oxides, r' being optionally substituted by C^-C^ alkyl, C^-C^ alkoxy, halo, hydroxy, oxo, cyano, 3-methylureido, phenyl, 25 phenoxy, pyridyl, acetyl, carbamoyl, N-mcthylcarbamoyl, (Cj-C^ 4 5 4 5 4 5 alkoxy)carbonyl, -NR R , or -SO^NR R , where either R and R .are 4 5 each independently II or C|-(^ alkyl or R and R together with the - 97 - nitrogen aton to which they are attached forn a pipcridlno, morpholino, 4-aethylpiper.izin-l-yl or 4-fornylpiperazin-l-yl group.
6. A compound as claimed in claim S wherein R^ is CH, N—H N— -a.x • -i a N Nil., N NH ii y 1 ^"3 a or -t A nhconikh. . N N Qr N— Nil - 98 -
7. A compound as claimed In claim 5 wherein R Is N O.
8, A compound ns rlnJroed In cJain 5 wherein R is -q ' n mh ' \ CH. Ph ; \n , -Q • <5 ■ ■ Y-ONIU \ ^ _/ /*h <0 / ^ / \ m N-cn, NHCH o~ -fi ' <51 7 M.—' ' N=/ ' N =* > \ K o - OiPr OPh O -O -O"' N—^ ' N H-&
9. A coapound as claimed In claim S wherein R^ in <] -if' ~<1
» N—I . ~X or N—V ii *o h coch 3 lO.A coapound as clalaed in claim 5 wherein R^ Is nll2 3
11. A compound as clalned In claim 5 wherein R Is NIJ .C / \ T" X" ■ JCrXT"^' N N
12. A compound as claimed in claim 5 wherein R"* Is CH .COOEt d . -a . -a. it. .CONHCII, If ■ ~<J • so^nmo^ - 100 -
13. A compound as claimed In claim S wherein R is o t N N or J ll— OCH, o t Jl—y— nh_
14. A compound as claimed in claim 5 wherein R is
15. A compound as claimed in claim 5 wherein R Is -O 1 2
16. A compound as claimed in claim 1, wherein R Is CH^, R 3 is C^Hji R is 2,3-dlchlprophonyl, and R Is a group of the formula n n 10 -A Jk (Clill ! «r a |ih.irm.iccutically acccpcnhlc acid addition salt thereof. - 101 -
17. A compound of the formula (I) as claimed in any one of the preceding claims, or a pharmaceutlcally acceptable acid addition salt thereof, for use as a medicament.
18. A pharmaceutical composition comprising a compound of the formula (I) as claimed in any one of claims 1 to 16, or a pharmaceutlcally acceptable acid addition salt thereof, together with a pharmaceutlcally acceptable diluent or carrier.
19. The use of a dihydropyrldlne as claimed in any one of' claims 1 to 16, or ph.-irnwio-titically acceptable acid addition salt thereof, for the manufacture of a medicament for treating lscliaemlc heart disease, angina or hypertension.
20. A dihydropyrldlne of the formula (I) given and defined In claim 1 or a pharmaceutlcally acceptable acid addition salt thereof, which Is any one of those specifically hereinbefore mentioned.
21. A process for preparing a dihydropyrldlne of the formula (I) given and defined in claim 1 or a pharmaceutlcally acceptable acid addition salt thereof, substantially as hereinbefore described with particular reference to the accompanying Examples.
22. A dihydropyrldlne of the formula (I) given and defined in claim 1 or a pharmaceutlcally acceptable acid addition salt thereof, whenever.prepared by a process claimed in claim 21.
23. A pharmaceutical composition according to claim 18, substantially as hereinbefore described. F. R. KELLY ft CO., AGENTS FOR THE APPLICANTS.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE2240/85A IE56385B1 (en) | 1983-12-20 | 1983-12-20 | Dihydropyridine intermediate |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8236347 | 1982-12-21 | ||
| IE2240/83A IE55972B1 (en) | 1982-10-07 | 1983-09-23 | Phenylindene derivatives,acid addition salts thereof,and methods of preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE833010L true IE833010L (en) | 1984-06-21 |
| IE56384B1 IE56384B1 (en) | 1991-07-17 |
Family
ID=26284749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE3010/83A IE56384B1 (en) | 1982-12-21 | 1983-12-20 | Dihydropyridines |
Country Status (1)
| Country | Link |
|---|---|
| IE (1) | IE56384B1 (en) |
-
1983
- 1983-12-20 IE IE3010/83A patent/IE56384B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE56384B1 (en) | 1991-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0553191B1 (en) | Pyridine and pyridine n-oxide derivatives of diarylmethyl- piperidines or piperazines, compositions and use thereof | |
| US3133081A (en) | J-aminoindazole derivatives | |
| US4076820A (en) | Benzoquinolizines and hypotensive compositions containing them | |
| US3995039A (en) | Pyrazolo [1,5-a] [1,3,5] triazines | |
| EP0116769B1 (en) | Dihydropyridines | |
| US4616024A (en) | Dihydropyridine anti-ischaemic and antihypertensive agents | |
| CA1168232A (en) | Isoquinoline derivatives, a process for their preparation, pharmaceutical formulations containing them and their use | |
| PL113082B1 (en) | Method of guanidine derivatives preparation | |
| US4568677A (en) | 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents | |
| US4515799A (en) | Dihydropyridine anti-ischaemic and antihypertensive agents | |
| JPH0499768A (en) | 4-(4-phenylpyridin-2-yl)piperazine-1-oxide derivative | |
| US4618609A (en) | Anti-ischaemic and antihypertensive 2-[pyrimidyloxy alhoxymethyl]-1,4-dihydropyridines | |
| US3989709A (en) | Fused ring benzimidazole derivatives | |
| JPS6031825B2 (en) | Method for producing new piperidine derivatives | |
| Baggaley et al. | Inhibitors of blood platelet aggregation. Effects of some 1, 2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen | |
| US4548935A (en) | Dihydropyridine anti-ischaemic and anti-hypertensive agents, compositions and use | |
| US4150132A (en) | Oxadiazolopyrimidine derivatives | |
| CS248720B2 (en) | Production method of quinolines | |
| EP0161498B1 (en) | Phenylpiperazine derivatives and their acid addition salts | |
| CA1285945C (en) | N-¬¬¬1-(2)naphthylenemethyl or quinol-6-ylmethyl)-4- piperidinyl|amino|-carbonyl|-6-quinolinecarboxamide compounds | |
| US5071849A (en) | Dihydropyrimidothiazine derivatives | |
| AU597600B2 (en) | Dopamine-beta-hydroxylase inhibitors | |
| USRE28939E (en) | 3-Aminoindazole derivatives | |
| JPS58201764A (en) | Dihydropyridine derivative | |
| US4235910A (en) | Benzoquinolizines having blood pressure lowering activity, and in some instances, anti-secretory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |